感染

订阅

MedSci主页 / 所有栏目 / 感染

PLOS Pathog：发现一种抗病毒蛋白可能阻止黑猩猩传播HIV前体

2017-12-22 佚名 medicalxpress

抗病毒HIV前体
关注

在人类中，被称为APOBEC3H的抗病毒蛋白质可以抵抗产生HIV-1的病毒的黑猩猩的跨物种传播。德国杜塞尔多夫海因里希 - 海涅大学的Zeli Zhang及其同事在一项新的PLOS病原体研究中介绍了这一发现。

在人类中，被称为APOBEC3H的抗病毒蛋白质可以抵抗产生HIV-1的病毒的黑猩猩的跨物种传播。德国杜塞尔多夫海因里希 - 海涅大学的Zeli Zhang及其同事在一项新的PLOS病原体研究中介绍了这一发现。

APOBEC3H或A3H是几种称为A3的抗病毒蛋白质之一，其抑制慢病毒（一种包括HIV-1的病毒属）的复制。 HIV-1起源于黑猩猩免疫缺陷病毒（SIVcpz）株传播给人类。然而，很少有研究探索人类A3s对SIVcpz的影响。

在这项新的研究中，Zhang和同事研究了黑猩猩和人类中的A3蛋白如何影响SIVcpz。他们用SIVcpz菌株在不同A3的存在下从实验室细胞系感染细胞。使用一种新的方法，SIVcpz病毒经过基因修饰后能在一定条件下发光，从而使研究人员能够量化其在细胞中的传染性。

研究人员发现，人类A3蛋白A3H单体型II强烈抑制SIVcpz。这是由于A3H对SIVcpz蛋白质的抗性，这种蛋白质被称为Vifs，可以抵抗A3s。 A3H可以以不同的形式出现，而其他形式的人类A3H表现出与SIVcpz类似的活性。

使用来自大猩猩基因组计划的基因组测序数据，研究小组还发现人类A3H比黑猩猩A3H具有更广泛的不同可能形式。进一步的实验表明，来自SIVcpz和大猩猩SIV的Vif蛋白能够降解黑猩猩A3H，但不能降解A3H单体型II。

总体而言，这些发现表明人类A3H可以防止黑猩猩向人传播SIVcpz。因此，导致HIV-1的SIVcpz菌株的传播可能已经在具有不稳定形式的A3H的人中开始。

原始出处：

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (16)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-07-02 budeshao

    #黑猩猩#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-04-30 neurosurgeon

    #病毒蛋白#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-02-19 makuansheng

    #抗病毒蛋白#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-01-14 zzl0611_64089391

    签到学习了

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-01-03 杨柳青青

    签到学习了--

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-01-02 杨柳青青

    签到学习了--

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2018-01-01 杨柳青青

    签到学习了--

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2017-12-31 杨柳青青

    签到学习了--

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2017-12-30 杨柳青青

    签到学习了--

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1702880, encodeId=14961e0288085, content=<a href='/topic/show?id=1edc10330893' target=_blank style='color:#2F92EE;'>#黑猩猩#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=103308, encryptionId=1edc10330893, topicName=黑猩猩)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0b2b30431820, createdName=budeshao, createdTime=Mon Jul 02 19:36:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1705263, encodeId=d8cc1e0526303, content=<a href='/topic/show?id=03a2e0984af' target=_blank style='color:#2F92EE;'>#病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70984, encryptionId=03a2e0984af, topicName=病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6530955845, createdName=neurosurgeon, createdTime=Mon Apr 30 18:36:00 CST 2018, time=2018-04-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1927188, encodeId=ecde192e1889d, content=<a href='/topic/show?id=b4e8554863b' target=_blank style='color:#2F92EE;'>#抗病毒蛋白#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55486, encryptionId=b4e8554863b, topicName=抗病毒蛋白)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2ba9118, createdName=makuansheng, createdTime=Mon Feb 19 21:36:00 CST 2018, time=2018-02-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=278269, encodeId=32092e826985, content=签到学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f6352227688, createdName=zzl0611_64089391, createdTime=Sun Jan 14 01:43:16 CST 2018, time=2018-01-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=275010, encodeId=5c132e501076, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Wed Jan 03 10:45:51 CST 2018, time=2018-01-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274775, encodeId=7ebd2e47750d, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Tue Jan 02 15:41:25 CST 2018, time=2018-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274453, encodeId=cb5a2e4453be, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Mon Jan 01 10:20:30 CST 2018, time=2018-01-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=274254, encodeId=96022e4254e2, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sun Dec 31 20:22:10 CST 2017, time=2017-12-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273924, encodeId=1be22e392473, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Sat Dec 30 20:11:40 CST 2017, time=2017-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=273613, encodeId=f1ea2e361326, content=签到学习了--, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=eeef1960262, createdName=杨柳青青, createdTime=Fri Dec 29 19:48:53 CST 2017, time=2017-12-29, status=1, ipAttribution=)]
    2017-12-29 杨柳青青

    签到学习了--

    0

以上为热门评论，梅斯医学App还有更多内容

相关资讯

全口服直接抗丙肝病毒治疗方案获批中国上市

我国目前约有1000万丙型肝炎（丙肝）病毒感染者，且丙肝新报告病例已从2003年的每年2.1万例增至2016年的每年23万例。与此同时，中国的丙肝诊断率仅为2%且诊断前知道什么是丙肝的人不足25%。丙肝慢性化概率高，易发展为肝硬化甚至是肝癌。

JAMA Neurol：HIV感染及抗病毒治疗对患者大脑结构及认知的影响

研究发现，血清转换早期，HIV感染者认知与大脑结构即以发生变化，持续的抗病毒治疗能预防或减少进行性脑损伤的发生

Aliment Pharmacol Ther：直接抗病毒治疗丙肝患者的成本效果如何？

2017年10月，发表在《Aliment Pharmacol Ther》上的一项系统评价，考察了直接抗病毒药物治疗基因型2-6丙肝的成本效果。结果显示：在$100000/QALY阈值时，基因型2-5的丙肝病毒（HCV）患者中直接抗病毒药物的HCV治疗具有较高的成本效果。从公众健康和经济角度，及时HCV治疗可能是一个最佳策略。

PNAS:科学家发现中国“蜱虫病”病毒的“阿喀琉斯之踵

中国科学院微生物研究所高福团队与遗传与发育生物学研究所博士高峰首次解析了两种布尼亚病毒囊膜蛋白Gn的结构以及其中一种重要病原新布尼亚病毒（又称发热伴血小板减少综合征病毒，SFTSV）的Gn与中和抗体的复合物结构，为疫苗与抗病毒药物的研发提供了重要的理论依据。

JCO：病毒特异性T细胞可以抗病毒？

大家都知道改善异基因造血干细胞移植（HSCT）患者的治愈率需要减少严重病毒感染引起的治疗相关死亡率，但如何减少却是一个问题。有研究表明从有资格的第三方捐助者产生的过继转移的病毒特异性T细胞（VSTs）可能会对接受HSCT的患者产生广泛的抗病毒保护作用，而且是立即可用的现成产品。

Eur J Gastroenterol Hepatol：丙肝抗病毒治疗后肝硬度值下降、肝纤维化逆转

根除HCV后，丙肝患者的肝脏病变是否不再进展，或者更进一步实现逆转？